Informazioni
Non ci sono recensioni
History of Pineal Gland as Neuroendocrine Organ and the Discovery of Melatonin
Pages 1-23
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Melatonin, Neuroprotective Agents and Antidepressant Therapy
López-Muñoz, Srinivasan, de Berardis, Álamo, Kato
Editore
Springer
Anno
2016
Pagine
921
ISBN
9788132228011
259,00 €
DA SCONTARE
This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects. .
-
-
Bibliometric Study of Scientific Research on Melatonin During the Last 25 Years
Pages 25-42
-
Neuroimaging of the Pineal Gland: Focus on Primary Insomnia
Pages 43-53
-
Melatonin: Basic and Clinical Aspects
Pages 55-64
-
Melatonin and Melatonin Receptors in Neuroprotection
Pages 65-75
-
Melatonin Supplementation in Neurodegenerative Diseases: Current Status
Pages 77-89
-
Therapeutic Potential of Melatonin in Combination with Other Drugs Against Neurodegeneration
Pages 91-99
-
Melatonin, a Neuroprotective Agent: Relevance for Stress-Induced Neuropsychiatric Disorders
Pages 101-115
-
Melatonin, Sleep, Circadian Rhythm, and Mood Disorders
Pages 117-127
-
Melatonin Induces Antidepressant-Like Behavior by Promotion of Adult Hippocampal Neurogenesis
Pages 129-136
-
Association Between Melatonin and Neuroimmune Diseases
Pages 137-149
-
Melatonin in Clinical Status of Patients with Fibromyalgia Syndrome
Pages 151-163
-
Melatonin’s Beneficial Effects in Hepatic Injury
Pages 165-175
-
Melatonin as a Novel Therapeutic Agent Against Chemical Warfare Agents
Pages 177-191
-
New Galenic Formulations of Melatonin
Pages 193-202
-
Melatonergic Drug Ramelteon in Neurotherapeutics
Pages 203-217
-
Melatonergic Antidepressant Agomelatine and Its Efficacy in Depressive Disorders
Pages 219-228
-
Agomelatine, Melatonin and Depression
Pages 229-247
-
Neuropsychological Models of Depression
Pages 249-271
-
Chronobiology of Mood Disorders
Pages 273-295
-
Bipolar Disorders and Biological Rhythms
Pages 297-317
-
Circadian Clock Genes and Mood Disorders
Pages 319-334
-
Understanding the Biologically Adaptive Side of Mood Disorders: A Focus on Affective Temperaments
Pages 335-346
-
Sleep Abnormalities as a Diagnostic Tool for Major Depressive Disorder
Pages 347-356
-
Depression: Correlations with Thyroid Hormones in Major Depressive Disorder
Pages 357-363
-
History of the Discovery of Antidepressant Drugs
Pages 365-383
-
Neurocognitive Deficit in Bipolar Disorders
Pages 385-420
-
Combination Strategies in Treatment-Resistant Depression
Pages 421-444
-
Antidepressant Drugs in Elderly
Pages 445-463
-
Antidepressant Efficacy of Escitalopram in Major Depressive Disorder
Pages 465-476
-
Antidepressant Medications and Suicide Risk: What Was the Impact of FDA Warning?
Pages 477-499
-
Neurobiology and Pharmacological Prevention of Suicide in Mood Disorders
Pages 501-522
-
Antidepressant and Anticonvulsant Drugs as Adjuvant Analgesics in Chronic Pain
Pages 523-532
-
Genetic Polymorphisms of Cytochrome P450 and Antidepressants
Pages 533-543
-
Pharmacogenomics of Antidepressant Drugs
Pages 545-609
-
Antidepressants Modulate Microglia Beyond the Neurotransmitters Doctrine of Mood Disorders
Pages 611-620
-
Brain-Derived Neurotrophic Factor (BDNF): TrkB Signaling in Depression – Biomarker and Novel Therapeutic Target
Pages 621-629
-
Targeting Opioid Receptors for Innovative Antidepressant Therapies: Rediscovering the Opioid Cure
Pages 631-653
-
Prolactin and Somatostatin Responses to Antidepressant Therapy
Pages 655-666
-
The Role of Vasopressin in Anxiety and Depression
Pages 667-685
-
Ketamine: The Glutamatergic Antidepressant and Its Efficacy
Pages 687-706
-
Acetylcholinergic Nicotinic Receptors as Pharmacological Targets for Cognitive Enhancement: Emerging Evidence from Psychosis Populations
Pages 707-730
-
The Glutamate mGluR5 Receptor as a Pharmacological Target to Enhance Cognitive Function: Emerging Evidence from Psychosis Models
Pages 731-750
-
Corticotropin-Releasing Factor Receptors as a Potential Target in the Developments of Antidepressant Drugs
Pages 751-764
-
Nitric Oxide Signaling in Depression and Antidepressant Action
Pages 765-792
-
The Role of Arrestins in the Neuroprotective Effects of Antidepressant Drugs
Pages 793-804
-
Antidepressant Drugs and Phosphodiesterases
Pages 805-823
-
Effects of Methylphenidate and Atomoxetine on Development of the Brain
Pages 825-845
-
S-Adenosyl-L-Methionine for Major Depressive Disorder
Pages 847-854
-
The Role of Antiepileptic Drugs in Bipolar Depression
Pages 855-868
-
Melatonin and Other Neuroprotective Agents Target Molecular Mechanisms of Disease in Amyotrophic Lateral Sclerosis
Pages 869-903
